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de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Cerdanyola del Vallès, Spain, 3 Unit of Infections and Cancer, Catalan Institute of Oncology – ICO-
Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain, 4 Hospital Clı́nico - Institut d’Investigacions Biomèdiques August Pi i Sunyer
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Abstract
Background: High-risk human Papillomavirus infection is a necessary factor for cervical squamous intraepithelial lesions and
invasive cervical cancer. In HIV-1-infected women, HPV infection is more prevalent and a higher risk of cervical cancer has
been identified. We aimed to calculate the prevalence of infection by HR-HPV, determine the factors associated with this
infection and abnormal cytology findings and to describe the history of cervical cancer screening in HIV-1-infected women.
Methods: We enrolled 479 HIV-1–infected women from the PISCIS cohort. Each patient underwent a gynecological check-
up, PAP smear, HPV AND Hybrid capture, HPV genotyping, and colposcopy and biopsy, if necessary. We applied
questionnaires to obtain information on sociodemographic, behavioral, clinical, and cervical screening variables. We present
a cross-sectional analysis.
Results: Median age was 42 years. The prevalence of HR-HPV infection was 33.2% and that of high-grade squamous
intraepithelial lesions (HSIL) was 3.8%. The most common genotypes were 16(23%), 53(20.3%), and 52(16.2%). The factor
associated with HR-HPV infection was age ,30 years (odds ratio[OR],2.5; 95%confidence interval[CI],1.1–5.6). The factors
associated with the presence of HSIL or low-grade squamous intraepithelial lesions (LSIL) were CD4T-lymphocyte count
,200cells/mm3 versus .500cells/mm3 (OR,8.4; 95%CI,3.7–19.2), HIV-1 viral load .10,000copies/mL versus ,400copies/mL
(OR,2.1; 95%CI,1.0–4.4), and use of oral contraceptives (OR,2.0; 95%CI,1.0–3.9). Sixty percent of HIV-1–infected women had
had one Pap smear within the last 2 years.
Conclusions: The high prevalence of HPV infection and cervical lesions in the HIV-1–infected population in Catalonia, as well
as the low coverage and frequency of screening in this group, means that better preventive efforts are necessary and should
include vaccination against HPV, better accessibility to screening programs, training of health care professionals, and
specific health education for HIV-1–infected women.
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Introduction
High-risk human papillomavirus infection (HR-HPV) is a
prerequisite for the development of squamous intraepithelial
lesions (SIL) and invasive cervical cancer (ICC). Several epidemi-
ological and molecular studies have established a causal associa-
tion between HPV and ICC [1,2].
ICC accounts for 9.8% of all human cancers, and every year
500,000 new cases are diagnosed throughout the world. Around
280,000 of these women die, and at least 80% of these deaths
occur in developing countries [3]. HPV 16, 18, 31, 33, 35, 45, 52,
and 58 cause more than 90.0% of all cases of ICC [4].
Spain has one of the highest prevalences of HIV-1 infection in
Western and Central Europe [5]. In 2006 in Catalonia, 32,932
individuals aged 15 to 64 years were infected by HIV-1. The
percentage of cases of AIDS diagnosed in women increased from
14.2% in 1986 to 21.9% in 2008. ICC was the defining disease in
4.9% of women diagnosed with AIDS during 1994–2008 [6].
In Spain, the annual incidence of ICC in women of all ages is
6.3 per 100,000 inhabitants and mortality is 1.9 per 100,000
inhabitants. In young women (15 to 44 years), the incidence of
ICC is 6.6 per 100,000, making it the second most common
cancer after breast cancer [7].
HIV-1–infected women are more susceptible to developing
HPV infection and SIL [8,9]. In Catalonia, the prevalence of HPV
infection in HIV-1–positive women exceeds 40%, much higher
than the 10% observed in the general population [10]. Similarly,
several studies have confirmed that, in Catalonia, the incidence of
ICC in HIV-1–infected women is high, with an incidence ratio of
18.5 between HIV-1–infected women and HIV-negative women
aged between 20 and 49 years [11,12].
Several authors have discussed the question of whether the high
prevalence of HPV infection and ICC in HIV-1–infected women
varies depending on the effectiveness of cervical screening
programs [13,14].
With the aim of studying the association between HIV-1
infection and HR-HPV in our setting, we selected a subcohort of
HIV-1–infected women from the PISCIS cohort (Project for
Electronic Clinical-Epidemiologic Follow-up of HIV-1 Infection
and AIDS). The objectives of the present study were to estimate
the prevalence of HR-HPV infection and SIL and associated
factors, to describe clinical-epidemiologic characteristics, and
examine the history of cervical cancer screening in this population.
Methods
Design
The present study was designed as a cohort of HIV positive
women from 9 hospitals included in PISCIS cohort. The presented
manuscript only shows a cross-sectional analysis of base line data
obtained during the first visit of the participating women to the
gynecologist. The recruitment period was from September 2007 to
March 2009
Study population
The study population was an opportunistic sample taken from
patients included in the PISCIS cohort [15]. The study included a
non-discriminatory inclusion, according to degree of immunosup-
pression, evolution of HIV infection and treatment. All women
seeking medical attention at the HIV Unit during the study period
were offered to participate. Patients who did not agree to
participate were excluded. The participants were referred once
or twice per year to the gynecology service of the hospital where
they were assisted.
Nine centers from Catalonia were responsible for recruiting and
following the women who participated in this study. The hospitals
were Hospital Clı́nico-IDIBAPS (Barcelona), Hospital Universi-
tario de Bellvitge (Hospitalet de Llobregat), Hospital de Mataró
(Mataró), Corporació Sanitària Parc Taulı́ (Sabadell), Hospital
Universitario Germans Trias i Pujol (Badalona), Hospital General
de L’Hospitalet (Hospitalet de Llobregat), Hospital de Palamós
(Palamós), Hospital Comarcal del Alt Penedès (Vilafranca del
Penedès), and Hospital de la Santa Creu i Sant Pau (Barcelona).
With an alpha error of 0.05, a hypothetical prevalence of HPV
of 45%, and a power of 80% for an odds ratio greater than or
equal to 1.9 in the risk factors study, the necessary sample size was
calculated to be approximately 500 women. The sample n = 500
considered an oversizing of 10% for attrition (losses) of the sample,
the power of 80% was considered for the original sample without
oversizing.
The ethics committees of the participating hospitals approved
the study and patients gave their signed informed consent to
participate. A total of 479 HIV-1–infected patients were recruited
during the study period.
Data collection instruments: questionnaires
Recruitment was carried out by internists who invited the
patient to participate in the project and obtained the informed
consent, they derived the recruited women to the gynecologist
participating in the study and communicated to the coordinating
center the number of women who had been recruited for the
study.
The study was very well accepted among the women
participating in the PISCIS Cohort and only 2 women refused
to participate.
At the first visit, a clinical-epidemiologic questionnaire consist-
ing of 40 questions to obtain information on sociodemographic,
behavioral, clinical, and cervical screening variables, was admin-
istered by the gynecologist. In addition, the questionnaire included
9 questions on screening history; these 9 questions were completed
by the gynecologist from medical records.
Collection and analysis of biological samples
All the patients on the first visit underwent a gynecological
check-up and two biological samples were obtained: a first sample
was taken for a conventional or liquid cytology test (PAP smear)
for subsequent processing at the hospital. A second sample was
taken to determine the presence of HPV DNA using a second-
generation hybrid capture assay (Digene HC2 DNA test,
QIAGEN Inc., Valencia, California, USA) and to genotype the
virus (LINEAR ARRAY HPV Genotyping Test, Roche Diagnos-
tics Corporation, Indianapolis, Indiana, USA). The second group
of samples was processed at the HPV laboratory of the Cancer and
Infections Unit (Catalan Oncologic Institute, Barcelona, Spain).
The frequency of the follow-up visits and treatment depended on
the results of the diagnostic tests: patients with normal cytology
results and negative HPV DNA results had a follow-up visit at 12
months. Patients with an abnormal cytology result or positive HR-
HPV, or both underwent colposcopy. Irrespective of the results of
colposcopy, patients attended a follow-up visit at 6 months. In
cases of an abnormal colposcopy result, a cervical biopsy was
performed according to the internal procedures of each hospital.
All those patients with cervical lesions were treated according to
care protocols.
The HC2 technique identifies HPV DNA using in vitro
hybridization with specific RNA probes and can detect 13 types
of HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68).
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Genotyping by Linear Array amplifies and detects a fragment of
HPV DNA. The PGMY09/11 primer set targets a 450-bp region
of the HPV L1 gene and can identify 37 types of HPV with a low,
high, and probable oncogenic risk (6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69,
70, 71, 72, 73, 81, 82, 83, 84, IS39, and Cp6108).
HIV data
In order to cross the HIV and HPV co infection data of women
participating in the study, data from HIV infection history (CD4
(cells/mm3), CV (copies/mL), treatment, etc.) of each patient were
retrieved from the PISCIS Cohort databases this information was
taken from the medical records. The data of CD4 and VL
measures included in the analysis was the obtained closer to the
date of the first visits to the gynecologist in the study of each
patient, the latest CD4 and VL that were in medical records.
Statistical analysis
Quantitative variables were described using the median
(interquartile range [IQR]); qualitative variables were described
using percentages. Groups were compared using the Pearson x2
test; when the expected frequencies were less than 5, the Fisher
exact test was applied. Univariate and multivariate logistic
regression models were applied to identify possible factors
associated with HR-HPV infection and the presence of abnormal
cytology findings (high-grade squamous intraepithelial lesions
[HSIL] and low-grade squamous intraepithelial lesions [LSIL]).
The measure of association used was the odds ratio (OR), and a p-
value of ,0.05 was considered statistically significant. Data were
analyzed using SPSS version 17.0.
Results
Of the 11,374 patients comprising the PISCIS cohort, 2,519
(22.1%) were women. The population of the present study
comprised 479 HIV-1–infected women (19% of the total number
of women in PISCIS).
Table 1 shows the main sociodemographic, behavioral, clinical,
and history of cervical cancer screening variables. The median age
of the participants was 42 years. The main route of transmission of
HIV-1 was heterosexual relations (75.2%). Of all participating
Table 1. Main sociodemographic, behavioral, and clinical




















































Frequency of Pap smear (years)
Yearly 210 (50.6)
Every 2–3 years 105 (25.3)
Every 4–5 years 39 (9.4)
Every 6–10 years 34 (8.2)
,1 every 10 years 27 (6.5)
Total 415 (100)
{Present the valid percent, the total sample was n = 479 but there were some
missings data.
*Performed at the first visit to the study gynecologist.
1medical records.
aHAART was defined as the combination of at least 3 antiretroviral drugs.
Abbreviations: IVDU, intravenous drug user; STI, sexually transmitted infection;
HAART, highly active antiretroviral infection; ASC-US, atypical squamous cells of
undetermined significance; HSIL, high-grade squamous intraepithelial lesion;
LSIL, low-grade squamous intraepithelial lesion.
doi:10.1371/journal.pone.0047755.t001
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women, 66 (13.8%) were not in treatment and 413 (86.2%) were in
treatment. From those in treatment, 383 (92.7%) were on
HAART. Highly active antiretroviral therapy (HAART) was
defined as a regimen composed of at least 3 antiretroviral drugs.
The median CD4 T-lymphocyte count was 480 cells/mm3 (IQR,
331–702) and the median viral load was 50 copies/mL (IQR, 40–
584). Median time on treatment was 90 months (IQR, 43–132),
and the median time from diagnosis of HIV-1 infection
documented in the medical records was 119 months (IQR, 59–
191)
With regard to history of cervical cancer screening, 11% of the
number of women infected by HIV-1 had never had a Pap smear,
only 60.0% had had one Pap smear within the last 2 years, and
50.6% reported a frequency of annual screening.
Of the 479 patients comprising the study sample, 159 (33.2%)
had a positive result by HC2. The prevalence of infection by HR-
HPV according to age group is shown in Figure 1; prevalence was
higher among younger women and there was an increase after 50
years.
Genotyping was performed on all patients who were HPV (HR)
positive by HC2 (n = 159). Genotyping results were obtained for
148 (93.0%) patients, 11 (7%) were other values 0.
Thirty two (21.6%) women with genotyping results had only one
type of HPV, 116 (78.4%) women presented multiple infections.
Most of them had between 2 and 4 different types of HPV.
(60.1%) The distribution of genotypes is shown in Table 2. HPV16
only appeared as a single genotype causing infection in 5 cases
(3,4%). In the remaining cases appeared in combination with
other genotypes (Table 2).
The most prevalent types of HR-HPV and probable HR-HPV,
including single and multiple infections, were HPV 16 (23%,
n = 34), 53 (20.3%, n = 30), and 52 (16.2%, n = 24) (Figure 2). The
most prevalent LR-HPV types were HPV 42 (13.5%), HPV 62
and 84 with 12.8% and 11.5% respectively.
The results of the Pap smear were as follows: atypical squamous
cells of undetermined significance (ASC-US), 7.9% (n = 38); LSIL,
13.8% (n = 66); and HSIL, 3.8% (n = 18). Pap smear revealed that
84.8% and 100% of patients with LSIL and HSIL respectively had
HR-HPV. Similarly, 34.2% of patients with ASC-US and 20.2%
of patients with a normal cytology result had HR-HPV. The most
prevalent HR- HPV and probable HR-HPV types in HSIL,
including single and multiple infections, were 16 and 53 (37.5%
each) and 52 (31.3%), the most prevalent LR-HPV types in HSIL
were Cp6108 (37.5%), HPV 84 and 81 (25% each) and HPV IS36
y 67 (18.8% each)
The main differential characteristics in HIV-1–infected patients
according to the result of HC2 and cytology are shown in Table 3.
Most women with HR-HPV (82.3%) had their first sexual
intercourse at age 18 or earlier, and 61.0% of coinfected women
had taken oral contraceptives for more than 10 years. As for CD4
T-lymphocyte count, 45.0% of coinfected women had 200–500
cells/mm3; most women (64.7%) had a viral load of ,400 copies/
mL and 48.5% had taken antiretroviral treatment for ,60
months.
The only factor associated with HR-HPV infection was age:
women under 30 years had an OR of having HR-HPV infection
that was 2.5 (95% CI, 1.1–5.6) times greater than that of women
aged .40 (Table 4). The factors associated with a cytology finding
of LSIL or HSIL were CD4 T-lymphocyte count ,200 cells/mm3
versus .500 cells/mm3 (OR, 8.4; 95% CI, 3.7–19.2), viral load
.10,000 copies/mL versus ,400 copies/mL (OR, 2.1; 95% CI,
1.0–4.4), and use of oral contraceptives (OR, 2.0; 95% CI, 1.0–
3.9) (Table 5).
Discussion
Our study is the first multicenter study performed in Catalonia
to provide data on the prevalence of HR-HPV infection, cervical
Figure 1. Prevalence curve of HR-HPV infection by age group.
doi:10.1371/journal.pone.0047755.g001
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lesions, and the distribution of high-risk genotypes present in the
HIV-1–infected population. We also report data on history of
cervical cancer screening.
In HIV-1–infected women, viral persistence is greater and
clearance of HPV infection is lower than in immunocompetent
women; therefore, the prevalence of HPV infection observed in
this population is greater than in the general population, and the
risk of progression to high-grade lesions and cancer is also greater
[16,17,18]. We found prevalence of HR-HPV infection of 33.2%.
Although this prevalence is much higher than that observed in
general population in Spain (.10%) [19] but is lower than that
found in other Spanish studies involving HIV-1–infected women,
which show a prevalence .40% [20,10]. This discrepancy with
other studies in HIV women performed in Spain could be
explained because the prevalence of HPV varies with age and the
median age in our population was higher (42 years) and/or
differences in the detection technique.
In the present study, 78.4% of HIV-1–infected women had
multiple infections. Irrespective of the technique used to detect
HPV DNA, these data are consistent with the results of several
studies showing that HIV-1–infected women not only have a
greater prevalence of HR-HPV infection, but that they are also
infected by a wider variety of types HPV than immunocompetent
women [9,21].
As HIV-1 and HPV are both transmitted through sexual
relations and share risk factors for acquisition associated with
sexual practices, it is difficult to address the infections separately.
The diversity of genotypes and the high prevalence of multiple
infections in HIV-1–infected women can be explained more by the
effects of HIV-1–induced immunosuppression (modulation of the
immune response to HPV, local immunity, and genetic instability)
[22] than by risky sexual behavior [23,24].
Consistent with the results of previous studies in Spain [9,10],
the most prevalent genotypes found in the present study were 16
(23%), 53 (20.3%), and 52 (16.2%).
Infection by HR-HPV is necessary for the development of SIL
and ICC [1]. The prevalence of SIL is consistently higher in HIV-
1–infected women than in HIV-1–negative women [9,16].
When we analyzed the distribution of HPV in HSIL, we found
a high prevalence of multiple infections, together with the presence
of HPV genotypes with lower oncogenic potential. This is
probably because in HIV-1–infected women, whose immune
systems are weakened, these types of HPV are more likely to evade
the immune system and persist in preneoplasic lesions [16,17,18].
According Darwich L et al. [25] there is a high prevalence of
HPV 16 and 18 in cervical cancers in HIV positive and negative
women in Barcelona. In ICC the HPV 18 was significantly more
prevalent in HIV-positive women as opposed to HIV-negative
women (14% vs 1%). Our study shows a high prevalence of HPV
16 and 53 in HSIL (37.5% each) in HIV positive women, HPV 18
has a prevalence of 12.5%.
Unlike the general population, HIV positive women have a
wide range of genotypes in both HSIL and LSIL, probably by the
characteristics of sexual behavior and the reactivation of latent
infections, which can encourage infection by different HPV types.
Taken into account the high prevalence observed of HPV 16 and
18, it is important to consider anti-HPV vaccination as a primary
preventive measure in HIV positive women. Studies evaluating the
safety and immunogenicity of the quadrivalent human papilloma-
virus vaccine in HIV-infected women are in progress and are
certainly needed.
Differences in the capacity to evade the immune system have
been observed among different HPV types. It has been shown that
the infection by HPV 16 would not depend as much on immune
status, whereas infection by other less prevalent types would, as
these could be enhanced by suppression of the quality of the
immune response [26]. The presence of multiple types of HPV in
HIV-1–infected women in our study could be associated with a
greater risk of cervical lesions, although we would need to evaluate
follow-up data and thus establish the contribution of genotypes
Table 2. Prevalence single and multiple infections of HPV
types in HIV positive women and HPV 16 distribution.













HPV 16 distribution n (%)1
16 5 (3.4)
16 y 6 2 (1.3)
16 y 11 2 (1.3)
16 y 59 2 (1.3)
16 y 66 1 (0.7)
16 y 70 1 (0.7)
16,42 y 58 1 (0.7)
16,51 y 53 1 (0.7)
16,11 y 39 1 (0.7)
16,55 y 58 1 (0.7)
16,35 y 84 1 (0.7)
16,62 y 66 1 (0.7)
16,39 y Cp6108 1 (0.7)
16,54 y 61 1 (0.7)
16,59 y 81 1 (0.7)
16,18 y 72 1 (0.7)
16,11 y 42 1 (0.7)
16,31,42 y 53 2 (1.3)
16,18,35 y 62 1 (0.7)
16,6,45,51 y 53 1 (0.7)
16,53,59,67 y Cp6108 1 (0.7)
16,53,55,58,64 y 81 1 (0.7)
16,18,67,68,73 y 84 1 (0.7)
16,18,31,33,51,52 y 54 1 (0.7)
16,31,35,59,72,81 y IS39 1 (0.7)
16,6,40,52,56,61,67,73 y Cp6108 1 (0.7)
*Include LR-HPV, probable and HR-HPV types.
1% in relation to all women with genotyping (n = 148).
doi:10.1371/journal.pone.0047755.t002
Human Papillomavirus in HIV-1-Infected Women
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e47755
with a low oncogenic potential to the development of HSIL and
ICC in this group.
Data from the questionnaires and the clinical records show that
75.2% of women participating in the present study became
infected by HIV-1 as a result of heterosexual relations. The high
level of promiscuity in the study population—most participating
women had their first sexual intercourse before age 18 and the
proportion of monogamous relationships was low—could explain
why the most common variables associated both with HR-HPV
infection and with the presence of abnormal cytology findings
were not significant in this study.
The prevalence of HPV infection decreases with age [27].
Younger women present a higher prevalence of infection, due to
the characteristics of their cervical epithelium and sexual behavior.
We observed that the pattern of infection by age in HIV-1–
infected women seems to follow a curve very similar to that
observed in the general population, although with a higher
intensity, namely, younger women had a higher prevalence and
risk of infection by HR-HPV (Figure 1). We also observed an
increase in the prevalence of infection in the upper age range; this
observation has also been made in other populations and may be
due to several factors, such as changes in sexual behavior in
middle-aged women, high rates of persistence of HPV, or a
weakened immune system [28,29].
The relationship between antiretroviral therapy and the natural
history of HPV infection remains controversial. Whereas some
studies have not found a clear association between antiretroviral
therapy and the reduction in the prevalence of cervical lesions and
HPV infection [8,30], others point to the contrary in women who
receive antiretroviral therapy [31,32]. In the present study, we
found a clear association between immune status of HIV-1–
infected women and detection of HR-HPV and abnormal cytology
findings: 25.6% of women with an abnormal cytology finding had
a CD4 T-lymphocyte count ,200 cells/mm3 compared with
6.1% of women with a normal cytology result. A similar
association was found for detection of HR-HPV and shorter time
of treatment. However, these differences only persisted in the
multivariate analysis for abnormal cytology findings but not for
detection of HR-HPV—due to the existence of confounders such
as age or sexual behavior, also these women might have a poorer
follow up in general—and significance disappeared in the
multivariate analysis. In any case, longitudinal studies would be
necessary to ascertain whether immune reconstitution induced by
antiretroviral therapy has an effect on the development and
progression of cervical lesions in this group, as well as on the
incidence and persistence of HR-HPV infection.
The Catalonian Cervical Cancer Screening Protocol recom-
mends that HIV-1–infected women undergo 2 Pap smear
separated by an interval of 6 months or 1 Pap smear with
colposcopy. In addition, women should have an annual Pap
smear, or more frequent Pap smears if their CD4 T-lymphocyte
count is ,500 cells/mm3 or cytology findings are abnormal. The
present study revealed inadequate coverage and frequency of
cervical cancer screening in HIV-1–infected women: 60.0% had a
Pap smear within the last 2 years and 50.6% reported a frequency
of annual screening. The data showed an inadequate screening in
HIV positive women. It is necessary to design and to implement
specific protocols addressed to vulnerable populations.
Taking into account an estimated incidence of HSIL in the
Spanish general population of 10 per 100,000 inhabitants, we
would expect to find 0.047 cases of HSIL in 479 women, thus
confirming the finding that 18 cases of HSIL in our study sample
(n = 479) is much higher than expected in women from the general
population who receive regular gynecological care. These findings
are consistent with the high incidence of ICC found in HIV-1–
infected women in Catalonia [11,12].
Our study has some limitations. The prevalence of HR-HPV
infection was determined based on the sensitivity level set in HC2
for detection of high-risk types, and this limit has been clinically
validated in several randomized clinical trials. Higher sensitivity
limits or broader-spectrum primers could have revealed more
cases of HPV infection. However, these limitations did not affect
the objectives of the study: the wide scientific evidence available
shows that HR-HPV are the most important types of HPV at an
epidemiological level, since they cause more than 99% of cases of
ICC in both the general population and the HIV-1–infected
population. It has to be taken into account that the cohort
included a non-discriminatory sample, according to degree of
immunosuppression, evolution of HIV infection and treatment, as
a consequence, the population of women with recent infection
with HIV was not represented in our study. The sample included
only women who had a prolonged history of infection (median,
119 months). In addition, many were taking HAART (92.7%) and
the median age was high (42 years). These findings could represent
Figure 2. HR-HPV and provable HR-HPV* types-specific prevalence in HIV-1 positive women.
doi:10.1371/journal.pone.0047755.g002
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,30 15 (4.7) 22 (13.8) 0.001 25 (6.3) 12 (14.3) 0.05
30–40 107 (33.4) 57 (35.8) 137 (34.7) 27 (32.1)
.40 198 (61.9) 80 (50.4) 233 (59.0) 45 (53.6)
Marital status
No stable partner 163 (51.3) 93 (58.9) 0.117 198 (50.4) 58 (69.9) ,0.01
Stable partner 155 (48.7) 65 (41.1) 195 (49.6) 25 (30.1)
Age at first sexual intercourse (years)
#18 249 (78.1) 130 (82.3) 0.280 308 (78.2) 71 (85.5) 0.131
.18 70 (21.9) 28 (17.7) 86 (21.8) 12 (14.5)
Number of sexual partners to date
#5 174 (54.7) 82 (52.9) 0.821 219 (55.7) 37 (46.2) 0.343
06-oct 49 (15.4) 27 (17.4) 63 (16.0) 13 (16.3)
nov-20 52 (16.4) 22 (14.2) 57 (14.6) 17 (21.3)
.20 43 (13.5) 24 (15.5) 54 (13.7) 13 (16.2)
Number of sexual partners during the
last 6 months
None 84 (26.9) 43 (27.9) 0.500 104 (26.9) 23 (29.1) 0.004
1 210 (67.3) 98 (63.6) 262 (67.7) 46 (58.2)
.1 18 (5.8) 13 (8.5) 21 (5.4) 10 (12.7)
Use of condom (stable partner)1
Always 117 (57.6) 58 (61.1) 0.460 148 (58.7) 27 (58.7) 0.547
Sometimes 49 (24.2) 17 (17.9) 58 (23.0) 8 (17.4)
Never 37 (18.2) 20 (21.0) 46 (18.3) 11 (23.9)
Use of condom (casual partner)1
Always 26 (65.0) 13 (61.9) 0.820 28 (60.8) 11 (73.3) 0.491
Sometimes 7 (17.5) 3 (14.3) 9 (19.6) 1 (6.7)
Never 7 (17.5) 5 (23.8) 9 (19.6) 3 (20.0)
Time since oral contraceptives were last
taken (years)
,1 8 (3.8) 10 (10.0) 0.005 12 (4.9) 6 (9.8) 0.238
01-maig 15 (7.2) 17 (17.0) 23 (9.3) 9 (14.8)
06-oct 32 (15.4) 12 (12.0) 37 (15.0) 7 (11.5)
.10 153 (73.6) 61 (61.0) 175 (70.8) 39 (63.9)
CD4 T lymphocytes (cells/mm3)
,200 16 (5.3) 27 (17.9) ,0.01 23 (6.1) 20 (25.6) ,0.01
200–500 128 (42.1) 68 (45.0) 160 (42.4) 36 (46.2)
.500 160 (52.6) 56 (37.1) 194 (51.5) 22 (28.2)
HIV-1 viral load (copies/mL)
,400 225 (79.2) 88 (64.7) 0.002 266 (76.7) 47 (64.3) 0.006
400–5,000 28 (9.9) 17 (12.5) 37 (10.7) 8 (11.0)
5,000–10,000 9 (3.2) 4 (2.9) 12 (3.5) 1 (1.4)
.10,000 22 (7.7) 27 (19.9) 32 (9.1) 17 (23.3)
Time on treatment (months)
,60 74 (26.5) 65 (48.5) ,0.01 100 (29.5) 39 (52.7) ,0.01
60–120 107 (38.4) 32 (23.9) 129 (38.1) 10 (13.5)
.120 98 (35.1) 37 (27.6) 110 (32.4) 25 (33.8)
*X2 test for linear trend.
**(low-grade squamous intraepithelial lesion and high grade squamous intraepithelial lesion).
1during the last 6 months.
doi:10.1371/journal.pone.0047755.t003
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an underestimation of HR-HPV infection and of cervical lesions in
this population. On the other hand, the sample was not
representative of the total HIV infected population in Catalonia,
however, when we contrast our data with the AIDS registry of
Catalonia, the clinical epidemiological characteristics did not
differ, moreover, the sample came from 9 hospitals that account
for 80% of HIV patients in Catalonia.
Finally, we retrieved the data closer to the date of 1st visit to the
gynecologist for each patient (at inclusion of patients in the study),
which means, the latest CD4 and VL who were in medical
records. The time frame was not defined, however, over 80% of
records corresponding to the last six months, both CD4 and VL.
In conclusion, we confirmed the high prevalence of HR-HPV
infection and cervical lesions in HIV-1–positive patients. HPV16
was the most prevalent type. The most important determinant of
HR-HPV infection was age less than 30 years. More abnormal
cytology findings were recorded in women with a poorer immune
status. Coverage and frequency of cervical cancer screening in
HIV-1–infected women in Catalonia is suboptimal, especially
considering the high-risk nature of this population. Optimizing
prevention of ICC is a priority in these patients.
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